Education
About Us
Working with TipRanks
Follow Us
Simulations Plus (SLP)
NASDAQ:SLP
SLP Stock Chart & Stats
$11.43
-$4.39(-14.45%)
At close: 4:00 PM EST
$11.43
-$4.39(-14.45%)
Day’s Range― - ―
52-Week Range$11.16 - $36.45
Previous CloseN/A
Volume738.72K
Average Volume (3M)354.79K
Market Cap
$246.39M
Enterprise Value$216.76M
Total Cash (Recent Filing)$35.69M
Total Debt (Recent Filing)$557.00K
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Apr 08, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding20,146,585
10 Day Avg. Volume287,303
30 Day Avg. Volume354,793
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.28
Price to Sales (P/S)3.60
P/FCF Ratio16.36
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit4.62
Enterprise Value/Ebitda14.82
Forecast
1Y Price Target
$19.00Price Target Upside66.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)1.02
Revenue Forecast (FY)$80.36M
Bulls Say, Bears Say
Bulls Say
Addressable Market And Regulatory TailwindsRising demand for simulation and modeling paired with regulatory shifts away from animal testing expands the long-term addressable market and boosts the case for broader customer adoption of biosimulation tools.
Product Innovation And AILaunch of GPX.2 as the first AI-powered release on the company’s cloud infrastructure signals meaningful product innovation that can attract customers seeking AI-driven simulation capabilities and support software adoption.
Services Backlog And Cross-sell PotentialA healthier services backlog, stronger bookings from large pharmaceutical customers, and an integrated platform roadmap increase opportunities for cross-selling and creation of new revenue streams.
Bears Say
Competitive Pressure And Valuation RiskPersistent competition and historical lagging revenue growth versus peers, combined with a premium valuation, create pressure for a material sales ramp to justify current stock pricing.
Guidance TransparencyReaffirmation of the near-term outlook without updated mid- or long-term guidance reduces visibility on the company’s longer-term revenue trajectory and heightens investor uncertainty.
Profitability And Acquisition ConcernsMisses on adjusted profitability and a significant write-down tied to a recent acquisition raise doubts about near-term earnings momentum and integration or asset-quality risks.
Simulations Plus News
SLP FAQ
What was Simulations Plus’s price range in the past 12 months?
Simulations Plus lowest stock price was $11.16 and its highest was $36.45 in the past 12 months.
What is Simulations Plus’s market cap?
Simulations Plus’s market cap is $246.39M.
When is Simulations Plus’s upcoming earnings report date?
Simulations Plus’s upcoming earnings report date is Apr 08, 2026 which is in 36 days.
How were Simulations Plus’s earnings last quarter?
Simulations Plus released its earnings results on Jan 08, 2026. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of N/A by $0.03.
Is Simulations Plus overvalued?
According to Wall Street analysts Simulations Plus’s price is currently Undervalued.
Does Simulations Plus pay dividends?
Simulations Plus pays a Quarterly dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Simulations Plus dividends here
What is Simulations Plus’s EPS estimate?
Simulations Plus’s EPS estimate is 0.31.
How many shares outstanding does Simulations Plus have?
Simulations Plus has 20,146,585 shares outstanding.
What happened to Simulations Plus’s price movement after its last earnings report?
Simulations Plus reported an EPS of $0.03 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 8.587%.
Which hedge fund is a major shareholder of Simulations Plus?
Currently, no hedge funds are holding shares in SLP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Simulations Plus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.00 (66.23% Upside)
$19.00 (66.23% Upside)
Blogger Sentiment
Bullish
SLP Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 476.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 10.6%
Last 30 Days ▼ 10.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.13%
12-Months-Change
Fundamentals
Return on Equity
-41.21%
Trailing 12-Months
Asset Growth
-30.01%
Trailing 12-Months
Company Description
Simulations Plus
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
SLP Company Deck
SLP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced results: the company delivered solid full-year organic growth, improved adjusted profitability, backlog expansion, product momentum in strategic areas (QSP, Monolix), and maintains a strong balance sheet with no debt. Offsetting these positives are a weak fourth quarter, pressure on renewals from client consolidations, select services and proficiency software softness in Q4, a meaningful reduction in reported profitability due to a $77.2 million noncash impairment producing a large GAAP net loss, and cautious near-term guidance (Q1 decline and modest FY growth range). Management emphasizes strategic investments in AI, cloud and an integrated ecosystem to capture long-term demand, but near-term uncertainty remains.View all SLP earnings summariesSLP Stock 12 Month Forecast
Average Price Target
$19.00
▲(66.23% Upside)
Technical Analysis
Ownership Overview
17.39% Insiders
14.66% Mutual Funds
13.98% Other Institutional Investors
44.10% Public Companies and
Individual Investors